Trial Profile
Lynparza Tablets 100mg, 150mg Clinical Experience Investigation (All Case Investigation) in Patients With Platinum-sensitive Relapsed Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2020
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 18 Dec 2020 Status changed from active, no longer recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 31 Oct 2020 to 30 Nov 2020.
- 17 Nov 2020 Planned primary completion date changed from 31 Oct 2020 to 30 Nov 2020.